ClinicalTrials.gg
Active, not recruitingNCT07624435CLONEUpdated Sep 17, 2026

Conventional Lead Opposed to Novel ECG (CLONE)

An observational study in ECG Monitoring, sponsored by HelpWear Inc.. Active, not recruiting at 2 sites in Canada. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by HelpWear Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
22 Years and older
Sex
All
01

Study summary

To blindly assess, beat-by-beat, standard ECG intervals (QRS intervals, PQ intervals, and P wave durations) of paired standard lead v4 with paired HeartWatch signals over 20 to 30 seconds of noise-free data.

Read the detailed description

This proof-of-concept study will enroll volunteers undergoing serial conventional 12-lead ECG rhythm strips who agree to wear a HeartWatch and use a Kardia mobile during those recordings.

The HeartWatch data will not be used for clinical decision-making. Rhythm strips from conventional 12-lead ECG recordings and the HeartWatch recordings will be obtained in volunteers in supine and standing positions and with the device placed in the recommended and in non-recommended positions (i.e., internally and externally rotated in keeping with the observed malposition identified in human factors testing environments (one inch or 2.5 cm; HelpWear, data on file).

Rhythm strips from serial 10-sec, 12-lead recordings will be obtained to allow for beat-by-beat comparisons of ECG intervals over the 20 to 30 seconds of noise free data. Specifically, the intervals from continuous v4 beats with paired continuous HeartWatch beats and the intervals from continuous lead I beats with paired continuous Kardia beats.

Since the HeartWatch is not intended to be used for evaluation of the ST segment or the QT interval, the comparison of the HeartWatch to standard lead v4 will exclude QT assessment.

02

Conditions studied

  • ECG Monitoring

Keywords

  • Heart Signals
  • ECG
03

In context

Lead sponsor

HelpWear Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Volunteers undergoing a conventional 12-lead ECG who agree to wear a HeartWatch and use a Kardia mobile device during that ECG recording.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 22 years of age at time of the conventional recording
  • Willing to participate in the study
  • Able to follow the protocol

Exclusion criteria

Exclusion Criteria

  • Known allergy to the electrodes used for a conventional
  • Known allergy to any component of the HeartWatch
  • Known allergy to any component of the Kardia system
  • Inability to wear the HeartWatch on the left arm due to pre-existing medical condition (e.g., functional AV fistula in left arm, prior carcinoma with lymph node dissection or lymphedema, known blood clot or recurrent blood clots in left arm, chronic neuropathic pain in left arm, …)
  • Dextrocardia
  • Implanted functional Pacemaker of Defibrillator
  • Left upper arm circumference \< 22 cm or > 45 cm
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (actual)
Patient registry
No

Groups and cohorts

  • Healthy volunteers

    Volunteers undergoing a conventional 12-lead ECG who agree to wear a HeartWatch and use a Kardia mobile device during that ECG recording.

    Device: ECG signals collection

Interventions

  • DeviceECG signals collection

    A Health-Canada and FDA-approved 12-lead ECG system (GE Healthcare, MAC 5500 or equivalent) will be used to collect the 10-sec digital rhythm strips in the noted supine and standing positions. A total of twenty-four (24) recordings, four from each of position, will be collected from each consenting participant: * Supine with HeartWatch in the recommended position * Standing with HeartWatch in the recommended position * Supine with HeartWatch in a one inch (2.5 cm) externally rotated position * Supine with HeartWatch in a one inch (2.5 cm) internally rotated position * Supine while collecting a 30-sec Kardia recording * Standing while collecting a 30-sec Kardia recording

    Also known as: Standard 12 lead ECG, Kardia ECG, Heartwatch ECG

06

What researchers measure

Primary outcomes

  1. Standard ECG and HeartWatch interval duration assessment in standard position

    The three co-primary efficacy endpoints for this study are beat-by-beat QRS intervals, PQ intervals, and P wave durations in continuous ECG (HeartWatch vs. lead v4 of a standard 12-lead ECG) in a supine position with the HeartWatch in the standard location.

    Time frame: The data for this outcome will be collected for each participant in their testing visit. All data is then assessed within two weeks of the data collection testing visit.

Secondary outcomes

  1. ECG interval assessment with the heart watch and the 12 Lead ECG in non traditional positions.

    Secondary efficacy endpoints for this study are beat-by-beat QRS intervals, PQ intervals, and P wave durations in continuous ECG (HeartWatch vs. lead v4 of a standard 12-lead ECG) in a: 1. standing position with the HeartWatch in the standard location; 2. supine position with the HeartWatch in a one inch (2.5 cm) externally rotated; 3. supine position with the HeartWatch in a one inch (2.5 cm) internally rotated.

    Time frame: The data for this outcome will be collected for each participant in their testing visit. All data is then assessed within two weeks of the data collection from their testing visit.

Other outcomes

  1. 12 Lead ECG and Kardia signal duration analysis from supine and standing positions

    Exploratory endpoints for this study, for comparative purposes, are beat-by-beat QRS intervals, PQ intervals, and P wave durations in continuous ECG (Kardia system vs. lead I of a standard 12-lead ECG) in supine and standing positions.

    Time frame: The data for this outcome will be collected for each participant in their testing visit. All data is then assessed within two weeks of the data collection from their testing visit.

  2. Device related adverse events.

    The safety endpoint for this study is the incidence of device-related adverse events.

    Time frame: Adverse events will be collected and assessed from all data collection visits immediately following every data collection visit. All adverse events will be followed until resolved or for up to 30 days after the event.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — This information will be used to validate a company's Intellectual property

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Mar 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 3, 2026
StartActual
Feb 18, 2026
Primary completionActual
Mar 24, 2026
CompletionEst.
Aug 1, 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07624435
Lead sponsor
HelpWear Inc.
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Feb 18, 2026
Primary completion
Mar 24, 2026
Completion
Aug 1, 2027 (estimated)
Last update
Sep 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion